← All countries · South-East Asia
97%
MCV1
2025 · WHO/UNICEF estimate
96%
DTP3
2025 · WHO/UNICEF estimate
96%
HepB3
2025 · WHO/UNICEF estimate
2
Measles cases
2025 reported
18
Pertussis (whooping cough) cases
2025 reported
Two kinds of number live on this page. Coverage is the share of the target cohort vaccinated, as estimated by WHO and UNICEF each July from the country's reports, surveys and other evidence, shown beside what the country itself reported. Reported cases are what the national surveillance system sent to WHO; they are a floor, not a count of infections. Every row carries a grade; hover or focus it for the reason, or read how grades are assigned.
Vaccination coverage
| Vaccine | Latest estimate | Country-reported | Trend since 2000 | Data quality |
|---|---|---|---|---|
| BCGTuberculosis vaccine at birth | 95%2025 · WHO/UNICEF estimate | 95.0% | A · strong | |
| DTP1First dose of diphtheria-tetanus-pertussis | 96%2025 · WHO/UNICEF estimate | 96.3% | A · strong | |
| DTP3Third dose of diphtheria-tetanus-pertussis (the WHO benchmark of a working programme) | 96%2025 · WHO/UNICEF estimate | 95.5% | A · strong | |
| IPV1First dose of inactivated polio vaccine | 96%2025 · WHO/UNICEF estimate | 91.1% | A · strong | |
| IPV completeInactivated polio vaccine, complete primary series | —% · Administrative (country-reported) | — | too few points | no data |
| MCV1First dose of measles-containing vaccine | 97%2025 · WHO/UNICEF estimate | 96.7% | A · strong | |
| MCV2Second dose of measles-containing vaccine | 95%2025 · WHO/UNICEF estimate | 95.3% | A · strong | |
| RCV1First dose of rubella-containing vaccine | 97%2025 · WHO/UNICEF estimate | 96.7% | A · strong | |
| HepB3Third dose of hepatitis B vaccine | 96%2025 · WHO/UNICEF estimate | 95.5% | A · strong | |
| HepB birthHepatitis B birth dose within 24 hours | —% · Administrative (country-reported) | — | too few points | no data |
| Hib3Third dose of Haemophilus influenzae type b vaccine | 96%2025 · WHO/UNICEF estimate | 95.5% | A · strong | |
| PCV1Pneumococcal conjugate vaccine, first dose | —% · Administrative (country-reported) | — | too few points | no data |
| PCV completePneumococcal conjugate vaccine, final dose of the schedule | —% · Administrative (country-reported) | — | too few points | no data |
| RotaCRotavirus vaccine, complete series | —% · Administrative (country-reported) | — | too few points | no data |
| Yellow feverYellow fever vaccine (countries at risk) | —% · Administrative (country-reported) | — | too few points | no data |
| MenAMeningococcal A conjugate (meningitis belt) | —% · Administrative (country-reported) | — | too few points | no data |
| JEJapanese encephalitis vaccine (countries at risk) | 97.9%2025 · Administrative (country-reported) | 97.9% | D · poor | |
| TCVTyphoid conjugate vaccine | —% · Administrative (country-reported) | — | too few points | no data |
| PABProtection at birth against neonatal tetanus (maternal tetanus doses) | 97%2024 · WHO/UNICEF estimate | 91.6% | B · good | |
| HPV dose 1, girlsHPV programme coverage, first dose, girls | 96%2025 · WHO/UNICEF estimate | — | C · weak | |
| HPV complete, girlsHPV programme coverage, complete series, girls | 74%2025 · WHO/UNICEF estimate | — | C · weak | |
| HPV dose 1, boysHPV programme coverage, first dose, boys | —% · Administrative (country-reported) | — | too few points | no data |
Reported vaccine-preventable disease
| Disease | Reported cases | Incidence rate | Trend since 2000 | Data quality |
|---|---|---|---|---|
| Measles all countries · vaccine evidence | 22025 | 0.1per 1,000,000 total population | B · good | |
| Rubella all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | B · good | |
| Congenital rubella syndrome all countries · vaccine evidence | 02025 | 0per 10,000 live births | B · good | |
| Mumps all countries · vaccine evidence | 1622025 | 7per 1,000,000 total population | A · strong | |
| Pertussis (whooping cough) all countries · vaccine evidence | 182025 | 0.8per 1,000,000 total population | A · strong | |
| Diphtheria all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | B · good | |
| Tetanus (total) all countries · vaccine evidence | 62025 | 0.3per 1,000,000 total population | B · good | |
| Neonatal tetanus all countries · vaccine evidence | 02025 | 0per 1,000 live births | B · good | |
| Polio (paralytic) all countries · vaccine evidence | 02021 | 0per 1,000,000 <15 population | D · poor | |
| Yellow fever all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | A · strong | |
| Japanese encephalitis all countries · vaccine evidence | 22025 | 0.1per 1,000,000 total population | A · strong | |
| Invasive meningococcal disease all countries · vaccine evidence | 122023 | 0.5per 1,000,000 total population | D · poor | |
| Typhoid all countries · vaccine evidence | 282025 | 1.2per 1,000,000 total population | B · good |
National schedule (latest WHO listing)
Show the schedule (32 rows)
| Vaccine | Dose | Age | Target group | Comment |
|---|---|---|---|---|
| BCGBCG (Baccille Calmette Guérin) vaccine | 1 | B | General/routine | |
| DTDT (Tetanus toxoid and diphtheria, children's dose) vaccine | 5 | Y5 | General/routine | |
| DTWPDTwP (Whole cell) vaccine | 4 | M18 | General/routine | |
| DTWPHIBHEPBDTwP-Hib-HepB (Whole cell) vaccine | 1 | M2 | General/routine | |
| DTWPHIBHEPBDTwP-Hib-HepB (Whole cell) vaccine | 2 | M4 | General/routine | |
| DTWPHIBHEPBDTwP-Hib-HepB (Whole cell) vaccine | 3 | M6 | General/routine | |
| HPV4HPV-4 (Human papillomavirus 4-valent) vaccine | 1 | Y11 | HPV for females only | Girls who have completed 10 years. Given in schools in Grade 6. Girls who have missed the vaccine or any drop outs, can obtain the vaccine from field clinics. 2nd dose is given after a period of 6 months |
| HPV4HPV-4 (Human papillomavirus 4-valent) vaccine | 2 | +M6 | HPV for females only | Girls who have completed 10 years. Given in schools in Grade 6. Girls who have missed the vaccine or any drop outs, can obtain the vaccine from field clinics. 2nd dose is given after a period of 6 months |
| IPV_FRACIPVf (Inactivated polio vaccine fractional dose) | 1 | M2 | General/routine | fractional dose |
| IPV_FRACIPVf (Inactivated polio vaccine fractional dose) | 2 | M4 | General/routine | fractional dose |
| JE_LIVEATDJE-Livatd (Japanese Encephalitis live-attenuated) vaccine | 1 | Y1 | General/routine | |
| MMRMMR (Measles, mumps and rubella) vaccine | 1 | M9 | General/routine | |
| MMRMMR (Measles, mumps and rubella) vaccine | 2 | Y3 | General/routine | |
| OPVOPV (Oral polio vaccine) | 1 | M2 | General/routine | |
| OPVOPV (Oral polio vaccine) | 2 | M4 | General/routine | |
| OPVOPV (Oral polio vaccine) | 3 | M6 | General/routine | |
| OPVOPV (Oral polio vaccine) | 4 | M18 | General/routine | |
| OPVOPV (Oral polio vaccine) | 5 | Y5 | General/routine | |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 6 | Y12 | General/routine | |
| TTTT (Tetanus toxoid) vaccine | 1 | 1st contact | Pregnant women | No documentary evidence of 6 scheduled tetanus containing vaccines in childhood, 1st dose after 12 weeks of POA in the 1st pregnancy, 2nd dose 6 weeks after the 1st dose. 3 doses in subsequent pregnancies |
| TTTT (Tetanus toxoid) vaccine | 2 | +W6 | Pregnant women | No documentary evidence of 6 scheduled tetanus containing vaccines in childhood, 1st dose after 12 weeks of POA in the 1st pregnancy, 2nd dose 6 weeks after the 1st dose. 3 doses in subsequent pregnancies |
| TTTT (Tetanus toxoid) vaccine | 3 | Pregnant women | No documentary evidence of 6 scheduled tetanus containing vaccines in childhood, 1st dose after 12 weeks of POA in the 1st pregnancy, 2nd dose 6 weeks after the 1st dose. 3 doses in subsequent pregnancies | |
| TTTT (Tetanus toxoid) vaccine | 4 | Pregnant women | No documentary evidence of 6 scheduled tetanus containing vaccines in childhood, 1st dose after 12 weeks of POA in the 1st pregnancy, 2nd dose 6 weeks after the 1st dose. 3 doses in subsequent pregnancies | |
| TTTT (Tetanus toxoid) vaccine | 5 | Pregnant women | No documentary evidence of 6 scheduled tetanus containing vaccines in childhood, 1st dose after 12 weeks of POA in the 1st pregnancy, 2nd dose 6 weeks after the 1st dose. 3 doses in subsequent pregnancies | |
| TYPHOID_PSTyphoid polysaccharide vaccine | 1 | Risk group(s) | high risk categories, food handlers. Districts are selected on transmission pattern and data. | |
| VITAMINAVitamin A supplements | 1 | M6 | General/routine | <5 years, every 6 months |
| VITAMINAVitamin A supplements | 2 | M12 | General/routine | <5 years, every 6 months |
| VITAMINAVitamin A supplements | 3 | M18 | General/routine | <5 years, every 6 months |
| VITAMINAVitamin A supplements | 4 | M24 | General/routine | <5 years, every 6 months |
| VITAMINAVitamin A supplements | 5 | M30 | General/routine | <5 years, every 6 months |
| VITAMINAVitamin A supplements | 6 | M36 | General/routine | <5 years, every 6 months |
| YFYF (Yellow fever) vaccine | 1 | Travellers | provided only for travellers to YF endemic countries |
Compare schedules across 31 countries on the schedule hub.
Data and sources
- Download this country's data (JSON): every year, every antigen and disease, with the grade reasons.
- Coverage: WHO/UNICEF Estimates of National Immunization Coverage (WUENIC) and country-reported administrative/official coverage, from the WHO Immunization Data Portal export downloaded 21 October 2026.
- Reported cases and incidence: WHO/UNICEF Joint Reporting Form, same export. Incidence denominators are stated per row.
- Schedule: WHO vaccine-schedule export, latest listing year.